India's Antibiotic Crisis Deepens: Government Warns Rajya Sabha of Indiscriminate Drug Use Fueling Resistance Epidemic

Spread the Message

Read Time:4 Minute, 11 Second

New Delhi, February 4, 2026 – The Indian government has alerted the Rajya Sabha that rampant indiscriminate and non-prescription use of antibiotics is driving a surge in antimicrobial resistance (AMR), complicating treatments for common infections like pneumonia and urinary tract infections. Minister of State for Health Prataprao Jadhav shared these concerns in a written reply, underscoring ongoing surveillance and regulatory efforts amid a national health emergency.

Alarming Rise in Resistance Rates

India faces one of the world’s highest AMR burdens, with WHO’s GLASS 2025 report revealing that in 2023, one in three bacterial infections resisted common antibiotics—double the global average of one in six. Pathogens like E. coli show over 60% resistance to ciprofloxacin and 40% to third-generation cephalosporins, while Klebsiella pneumoniae exhibits nearly 20% resistance to last-resort carbapenems. A recent Lancet study further highlighted that 83% of Indian patients carry multidrug-resistant organisms (MDROs), positioning the country at the epicenter of a “superbug explosion.”

These statistics reflect a steady escalation, with ICU infections by E. coli, K. pneumoniae, and S. aureus showing particularly high resistance levels. Environmental factors, including pharmaceutical pollution and poor sanitation, exacerbate the spread, turning routine ailments into life-threatening conditions.

Root Causes: Misuse and Accessibility

The government’s statement pins indiscriminate use—over-the-counter sales, self-medication, and incomplete courses—as the primary driver. India, the world’s largest antibiotic consumer, sees 59% of usage from WHO’s “Watch” category drugs meant for serious infections only. Loose regulations allow unapproved formulations to dominate nearly half of consumption, varying starkly by state due to uneven public health spending.

High infectious disease burden, malnutrition, and hospital-acquired infections compound the issue, with over 50% of ICU cases involving difficult-to-treat gram-negative pathogens. “The belief that ‘one pill cures everything’ is strengthening infections and weakening drugs,” echoed Prime Minister Narendra Modi in a recent address, aligning with ICMR findings on irrational use.

Government Response and Initiatives

Antibiotics fall under Schedule H and H1 of the Drugs and Cosmetics Rules, mandating prescriptions from registered practitioners, enforced by the Central Drugs Standard Control Organization (CDSCO). The National Programme on AMR Containment, led by the National Centre for Disease Control (NCDC), promotes surveillance, IEC materials, and Standard Treatment Guidelines integrated into health programs.

Launched in November 2025, NAP-AMR 2.0 (2025-2029) adopts a “One Health” approach, assigning timelines and budgets to over 20 ministries, from health to agriculture. Measures include infection prevention guidelines, prescription audits for NQAS certification, and state-level plans. Sales growth of antimicrobials is projected to temper in 2026 due to these stricter OTC curbs.

Expert Perspectives

“At AIIMS, we enforce strict protocols—antibiotics only on prescription, full course,” states Dr. M Srinivas, Director of AIIMS Delhi, emphasizing training and SOPs to curb misuse. Dr. Shiv Kumar Sarin, Director of the Institute of Liver and Biliary Sciences, warns that three in four hospital infections now resist common antibiotics, urging enforcement.

Dr. Kamini Walia from ICMR highlights self-medication’s role in superbug proliferation, predicting millions of deaths by 2050 without action. These voices stress stewardship: rational prescribing preserves efficacy for vulnerable patients.

Public Health Implications

AMR prolongs illness, spikes mortality, and inflates costs through extended stays and toxic alternatives, potentially reverting medicine to a pre-antibiotic era. In India, it threatens surgeries, chemotherapy, and transplants, with economic burdens from lost productivity. Globally, WHO projects 10 million annual deaths by 2050; India’s share could be disproportionate without curbing misuse.

For everyday health, it means simple UTIs or pneumonia may require hospitalization. Patients should complete courses, avoid self-treatment, and demand diagnostics before antibiotics—like checking if a fever needs viral care instead. High-burden groups, including children and the elderly, face amplified risks.

Challenges and Limitations

Despite progress, NAP-AMR 2.0 grapples with financial constraints, rural lab gaps, and weak enforcement. Surveillance varies regionally, underestimating true extent, while over-prescription persists in private sectors. Critics note fragmented efforts and low awareness hinder impact, with colistin resistance emerging despite low rates.

Implementation roadmaps are pending public release, and state disparities challenge uniformity. Broader issues like agriculture’s antibiotic use in livestock demand cross-sectoral vigilance.

Practical Steps for Readers

Consult doctors for infections; never buy antibiotics over-the-counter.
Finish prescribed courses to prevent survival of resistant strains.
Practice hygiene: handwashing reduces infection needs.
Support policies: advocate for audits and generic prescribing.
Stay informed via NCDC resources for rational use.

This crisis demands collective action—government resolve meets public discipline to safeguard antibiotics’ legacy.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.